Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment
OA: bronze
CC0
⤵ 5 in-corpus citations
AI-generated summary
Linzagolix treatment for 12 months effectively reduced endometriosis-associated pain and improved quality of life in patients with no significant safety concerns.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (6)
- Low-energy extracorporeal shock wave therapy is associated with reduced inflammation and fibrosis in an E2-induced rat model of endometriosis and remains effective under menopause-mimicking conditions 2026
- A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment 2023
- Hormonal drugs for the treatment of endometriosis 2022
- Linzagolix: First Approval 2022
- Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review 2021
- The oral gonadotropin-releasing hormone antagonists: contemporary possibilities and perspectives of application 2020
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK